Dani P. Bolognesi

Dr. Bolognesi is Professor Emeritus at Duke Medical Center, presently serving in a special capacity within Duke University Medical Center as Chair of the Joint Steering Committee of MedBlue Incubator, Inc. His scientific career spans 3 decades, during which he has held many positions at Duke University and been involved in all phases of drug development. He was also Founder, CEO, and Chief Scientific Officer at Trimeris, Inc., a publicly traded biotechnology company that successfully obtained FDA approval for Fuzeon®, a first-in-class HIV fusion inhibitor, and he led the execution of its development and commercial collaboration with F. Hoffmann-La Roche AG. He also served as CEO and Chairman of b3 bio, Inc.; CEO of Enci Therapeutics, Inc.; and CEO of C2 Regenerate, Inc.